Literature DB >> 500211

Susceptibility of inbred mice to chronic central nervous system infection by Theiler's murine encephalomyelitis virus.

H L Lipton, M C Dal Canto.   

Abstract

The present study demonstrated that the clinicopathological expression of the late demyelinating disease due to chronic central nervous system infection by Theiler's mouse encephalomyelitis virus was dependent, at least in part, on the strain of mouse used as host. A range of involvement was observed, with late disease being most severe in the SJL strain, intermediate in the CBA and C3H/He strains, and least in C57BL/6 mice. The lack of clinical signs in seven other inbred strains of mice indicates that their response to chronic infection was similar to C57BL/6 mice. SJL, CBA, C3H/He, and C57BL/6 mice all generated similar levels of neutralizing antibody. A correlation between the severity of late disease and central nervous system virus content was not demonstrated, which indirectly suggests an immunopathological rather than a cytolytic mechanism of myelin injury during the late disease period. Finally, in addition to being more extensive, SJL demyelinating lesions contained a disproportionately large number of macrophages compared with those of similar lesions in CBA and C3H/He mice.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 500211      PMCID: PMC414621          DOI: 10.1128/iai.26.1.369-374.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  11 in total

1.  Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination.

Authors:  H L Lipton
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

2.  Characterization of the TO strains of Theiler's mouse encephalomyelitis viruses.

Authors:  H L Lipton
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

3.  Control of in vitro and in vivo spread of coxsackievirus B4 infection by sensitized spleen cells and antibody.

Authors:  U C Chaturvedi; H O Tandon; A Mathur
Journal:  J Infect Dis       Date:  1978-08       Impact factor: 5.226

4.  The role of antibody and host cells in the resistance of mice against infection by coxsackie B-3 virus.

Authors:  B Rager-Zisman; A C Allison
Journal:  J Gen Virol       Date:  1973-06       Impact factor: 3.891

Review 5.  The concept of the activated macrophage.

Authors:  R J North
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

6.  Theiler's virus-induced demyelination: prevention by immunosuppression.

Authors:  H L Lipton; M C Dal Canto
Journal:  Science       Date:  1976-04-02       Impact factor: 47.728

7.  Chronic neurologic disease in Theiler's virus infection of SJL/J mice.

Authors:  H L Lipton; M C Dal Canto
Journal:  J Neurol Sci       Date:  1976-11       Impact factor: 3.181

8.  Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: a possible mechanism of inflammatory demyelination.

Authors:  W Cammer; B R Bloom; W T Norton; S Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

9.  Cellular immunity in chronic Theiler's virus central nervous system infection.

Authors:  S G Rabinowitz; H L Lipton
Journal:  J Immunol       Date:  1976-08       Impact factor: 5.422

10.  Induction of macrophage plasminogen activator by endotoxin stimulation and phagocytosis: evidence for a two-stage process.

Authors:  S Gordon; J C Unkeless; Z A Cohn
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

View more
  42 in total

Review 1.  Gender differences in autoimmunity associated with exposure to environmental factors.

Authors:  K Michael Pollard
Journal:  J Autoimmun       Date:  2011-12-03       Impact factor: 7.094

2.  Neurotropic viral infections leading to epilepsy: focus on Theiler's murine encephalomyelitis virus.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Future Virol       Date:  2011-11       Impact factor: 1.831

Review 3.  Strain-Related Differences in the Immune Response: Relevance to Human Stroke.

Authors:  Kyra J Becker
Journal:  Transl Stroke Res       Date:  2016-02-10       Impact factor: 6.829

4.  Transgenic expression of the 3D polymerase inhibits Theiler's virus infection and demyelination.

Authors:  Jason Kerkvliet; Laurie Zoecklein; Louisa Papke; Aleksandar Denic; Allan J Bieber; Larry R Pease; Chella S David; Moses Rodriguez
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

5.  Innate but not adaptive immune responses contribute to behavioral seizures following viral infection.

Authors:  Nikki J Kirkman; Jane E Libbey; Karen S Wilcox; H Steve White; Robert S Fujinami
Journal:  Epilepsia       Date:  2009-10-20       Impact factor: 5.864

6.  Lack of correlation of central nervous system inflammation and neuropathology with the development of seizures following acute virus infection.

Authors:  Jane E Libbey; Nikki J Kennett; Karen S Wilcox; H Steve White; Robert S Fujinami
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

7.  Three immune-mediated disease models induced by Theiler's virus: Multiple sclerosis, seizures and myocarditis.

Authors:  Ikuo Tsunoda; Fumitaka Sato; Seiichi Omura; Mitsugu Fujita; Namie Sakiyama; Ah-Mee Park
Journal:  Clin Exp Neuroimmunol       Date:  2016-10-25

8.  ICAM-1 is crucial for protection from TMEV-induced neuronal damage but not demyelination.

Authors:  Kristen M Drescher; Laurie J Zoecklein; Moses Rodriguez
Journal:  J Neurovirol       Date:  2002-10       Impact factor: 2.643

9.  The immune response to picornavirus infection and the effect of immune manipulation on acute seizures.

Authors:  Ana Beatriz DePaula-Silva; F Lynn Sonderegger; Jane E Libbey; Daniel J Doty; Robert S Fujinami
Journal:  J Neurovirol       Date:  2018-04-23       Impact factor: 2.643

10.  Identification of a locus on mouse chromosome 3 involved in differential susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Authors:  R W Melvold; D M Jokinen; S D Miller; M C Dal Canto; H L Lipton
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.